FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...

Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Lexi Reed's journey has continued to inspire many people. Recently she took to her official Instagram handle and shared an ...

An individual doesn’t develop heart disease in one day. It develops over several months and years. Therefore, it is crucial ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...